Your browser doesn't support javascript.
Identification of the metabolites of ivermectin in humans.
Tipthara, Phornpimon; Kobylinski, Kevin C; Godejohann, Markus; Hanboonkunupakarn, Borimas; Roth, Alison; Adams, John H; White, Nicholas J; Jittamala, Podjanee; Day, Nicholas P J; Tarning, Joel.
  • Tipthara P; Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
  • Kobylinski KC; Department of Entomology, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand.
  • Godejohann M; AIC, Bruker BioSpin GmbH, Rheinstetten, Germany.
  • Hanboonkunupakarn B; Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
  • Roth A; Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
  • Adams JH; Center for Global Health and Infectious Diseases Research, College of Public Health, University of South Florida, Tampa, FL, USA.
  • White NJ; Department of Drug Discovery, Experimental Therapeutics Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
  • Jittamala P; Center for Global Health and Infectious Diseases Research, College of Public Health, University of South Florida, Tampa, FL, USA.
  • Day NPJ; Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
  • Tarning J; Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom.
Pharmacol Res Perspect ; 9(1): e00712, 2021 02.
Article in English | MEDLINE | ID: covidwho-1482163
ABSTRACT
Mass drug administration of ivermectin has been proposed as a possible malaria elimination tool. Ivermectin exhibits a mosquito-lethal effect well beyond its biological half-life, suggesting the presence of active slowly eliminated metabolites. Human liver microsomes, primary human hepatocytes, and whole blood from healthy volunteers given oral ivermectin were used to identify ivermectin metabolites by ultra-high performance liquid chromatography coupled with high-resolution mass spectrometry. The molecular structures of metabolites were determined by mass spectrometry and verified by nuclear magnetic resonance. Pure cytochrome P450 enzyme isoforms were used to elucidate the metabolic pathways. Thirteen different metabolites (M1-M13) were identified after incubation of ivermectin with human liver microsomes. Three (M1, M3, and M6) were the major metabolites found in microsomes, hepatocytes, and blood from volunteers after oral ivermectin administration. The chemical structure, defined by LC-MS/MS and NMR, indicated that M1 is 3″-O-demethyl ivermectin, M3 is 4-hydroxymethyl ivermectin, and M6 is 3″-O-demethyl, 4-hydroxymethyl ivermectin. Metabolic pathway evaluations with characterized cytochrome P450 enzymes showed that M1, M3, and M6 were produced primarily by CYP3A4, and that M1 was also produced to a small extent by CYP3A5. Demethylated (M1) and hydroxylated (M3) ivermectin were the main human in vivo metabolites. Further studies are needed to characterize the pharmacokinetic properties and mosquito-lethal activity of these metabolites.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Ivermectin / Antiparasitic Agents Type of study: Experimental Studies Limits: Humans Language: English Journal: Pharmacol Res Perspect Year: 2021 Document Type: Article Affiliation country: Prp2.712

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Ivermectin / Antiparasitic Agents Type of study: Experimental Studies Limits: Humans Language: English Journal: Pharmacol Res Perspect Year: 2021 Document Type: Article Affiliation country: Prp2.712